SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

When Will Anavex 2-73 Get Prescribed?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
falconer66a Member Profile
 
Followed By 56
Posts 725
Boards Moderated 0
Alias Born 01/29/04
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/15/2017 4:13:15 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/15/2017 4:11:28 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 12/11/2017 5:17:35 PM
Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs "GlobeNewswire Inc." - 12/11/2017 7:00:00 AM
Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of... "GlobeNewswire Inc." - 11/21/2017 7:00:00 AM
Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington... "GlobeNewswire Inc." - 11/8/2017 7:00:00 AM
Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2-73 at 2017 Clini... "GlobeNewswire Inc." - 11/4/2017 3:30:00 PM
Greenbank Cap, Inc. (OTC Pink: GRNBF) Closes Private Placement as Shares Climb "InvestorsHub NewsWire" - 10/30/2017 7:00:00 AM
Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson's Disease Therapeutics Conferen... "GlobeNewswire Inc." - 10/30/2017 7:00:00 AM
Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017 "GlobeNewswire Inc." - 10/27/2017 8:52:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/26/2017 2:50:54 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/24/2017 12:06:59 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/19/2017 6:47:52 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/18/2017 9:47:41 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/16/2017 11:07:52 AM
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Pat... "GlobeNewswire Inc." - 10/12/2017 7:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/6/2017 5:18:01 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/5/2017 5:57:37 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/2/2017 7:53:34 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/29/2017 2:33:03 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/26/2017 3:10:51 PM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference "GlobeNewswire Inc." - 9/21/2017 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/20/2017 4:51:51 PM
Biotech's Recently Under the Microscope, Analyst Coverage "InvestorsHub NewsWire" - 9/20/2017 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/19/2017 1:59:44 PM
falconer66a   Thursday, 10/12/17 11:06:44 PM
Re: None
Post # of 134637 
When Will Anavex 2-73 Get Prescribed?

Let’s assume, quite reasonably, that the upcoming Phase 3 clinical trial, using updated designs and measurements, produces data similar to the Australian trial. Should those data be similar, FDA approval would be forthcoming, inasmuch those data already eclipse the existing standard of care data, from any of the four standard of care Alzheimer’s drugs, primarily Aricept (donepezil).

Presently, comments are being posted here with concerns regarding the fraction of trial participants with superior cognition improvements, and strength of those. The newly-released data show that Anavex 2-73 did not produce universal cognition improvement; only for fraction of the patients in that study. Therefore, the drug is perceived or presented as not as powerful or universally applicable as hoped or presumed by some.

But those data and findings are likely to be clinically irrelevant, when physicians have Anavex 2-73 available for each and every dementia patient they treat.

It won’t be like this. “Mrs. Jones, it was good that you brought your husband in here. He does have early-stage cognitive decline. He is in the first stages of Alzheimer’s, unfortunately. But in a year or two, there is great hope for him. We now have this new drug, Anavex 2-73, and for 25 to 50% of mid to mild Alzheimer’s patients, it gives wonderful stabilization of thinking, even improving it in many. So just take care of your husband a bit longer, until we assess that he’s progressed to the mid to mild stages of Alzheimer’s. Then, replicating the big Anavex study last year, we’ll start him on the drug. Right now, he’s not suffering enough yet. Next patient, please.”

No, there will be absolutely no reason not to begin Anavex 2-73 treatment at the very first indication of dementia onset. In short, clinical use of the drug will not be restricted to a patient cohort paralleling the mid to mild stage Alzheimer’s patients in the FDA-approval Phase 3 study. The drug will be given at the very earliest stages of Alzheimer’s dementia, for which there is currently no clinical response data.

There is every good reason to believe that early, even prophylactic administration of Anavex 2-73 will yield symptomatic relief greater than seen in the Phase 3 clinical data. Those data will have been taken from patients with well-developed, rather advanced Alzheimer’s symptomotology. Ethically and practically, physicians won’t be waiting to prescribe Anavex 2-73 only to those with advanced symptoms. They will be writing prescripts at the earliest signs of any geriatric dementia — with a consequently greater likelihood of profound relief. Early detection; early treatment. No reason to limit treatment to populations used in the clinical trial. Consequently, results will be better than the Phase 2 and Phase 3 data. Early treatment will be better treatment. Amyloid plaques and tau tangles will be much smaller; far more amenable for successful Anavex treatment.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist